HOOK - Hookipa gains on upcoming presentation on cancer drug

2023-04-26 15:17:26 ET

• Shares of immunotherapy company Hookipa Pharma ( NASDAQ: HOOK ) rose for the fourth consecutive session after announcing that it is scheduled to present an overview of its ongoing Phase 1/2 trial for prostate cancer drug HB-300 at an upcoming medical event.
• The company said that a Trial in Progress poster on the study had been accepted for a presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 03.
• An arenavirus-based cancer immunotherapy, HB-300, is targeted at patients with metastatic castration-resistant prostate cancer, and it is Hookipa’s ( HOOK ) second oncology immunotherapy program in the clinic.
• “We’re excited to present an overview of our ongoing HB-300 Phase 1/2 clinical trial at ASCO,” Chief Executive Joern Aldag remarked.
• Read: Seeking Alpha analyst Biologics issued a Buy rating on HOOK in April, noting the stock can trade in line with peers in the event of a positive catalyst.

For further details see: